Biogen Idec, Elan plan to seek FDA's OK to resume Tysabri sales

Biogen Idec and Elan say they will soon seek the FDA's permission to put Tysabri for multiple sclerosis back on the market. The drug was pulled earlier this year after three patients taking the drug contracted a rare form of brain disease--progressive multifocal leukoencephalopathy, or PML. Two of those patients died. The companies did not say exactly when they would seek regulatory permission to resume sales of the drug. A safety review was expected to be complete by today, but Biogen Idec now expects that review to be done in "coming weeks."

- read this story from MarketWatch for more